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Case Report
Acute Psychosis with Recurrent Neurocysticercosis:
A Case Presentation
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Neurocysticercosis, a parasitic infection of the central nervous system (CNS) caused by
the Taenia solium cestode, presents clinically with a large and diverse spectrum of symptomatology, dependent upon lesion number, locale and ensuing inflammatory response. To
this date, there are only two documented cases of psychosis presenting in patients with
neurocysticercosis, both of which were published in India. This case presentation depicts the
first documented case of Psychotic Disorder Due to Another Medical Condition: Neurocysticercosis in the United States. The authors postulate that the atypical presentation of the
neuropsychiatric instability with the aberrant recurrence of neurocysticercosis is predominantly attributable to the parasitic infection itself, along with its resultant cyst formation
and inflammatory response. Further research is necessary to expand upon our knowledge
and understanding of the neuropsychiatric effects and optimal management of neurocysticercosis, as well as its possible recurrent nature.
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Introduction

Neurocysticercosis, a parasitic infection of
the CNS by the Taenia solium cestode, is most
commonly transmitted through the ingestion
of undercooked pork or fecal-orally via contaminated water (larval cysts) in endemic areas
including South America, Africa and Asia.1,2
Following ingestion, the larval cysts are carried
in the bloodstream before depositing in the
brain.2 Classified as a “major neglected disease”
by the World Health Organization (WHO) due
to the lack of information regarding its burden, transmission and diagnostic resources,
the prevalence of neurocysticercosis in the
United States (US) remains unknown, as only
four states require its reporting.3 An estimated
prevalence of 15-38% exists within Latin American countries, and an estimated 1,320-5,050
new cases of neurocysticercosis occur yearly
in the United States (US). There is a higher
incidence noted among Hispanic patients.3

Clinical manifestations of neurocysticercosis
are dependent upon the exact location and the
number of lesions present, with a multitude of
diverse presentations demonstrated throughout the literature. However, the most common clinical manifestations are predominantly
neurological in nature, with the most prevalent
conditions reported to be epilepsy and intracranial hypertension (ICH).2 To date, there are only
two documented cases of psychosis presenting in patients with neurocysticercosis, both in
India.4,5

Case Presentation

The patient is a 21-year-old Peruvian female
with a past medical history of neurocysticercosis with resultant tonic-clonic seizures and as
well as migraine headaches with photophobia,
presenting to the hospital for altered mental
status (AMS) with orientation to person and
time only. The patient has a previous history of
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neurocysticercosis in 2012 while living in Peru,
with documented imaging of a single cyst in
the right frontal lobe, treated with an unknown
antiparasitic agent for 2 weeks and antiseizure
medication for 1 month, with no follow-up care
nor repeat imaging. The patient resides in the
US, but reported yearly visits to Peru for about
60 days per visit since 2012. The patient denied
any psychiatric history, history of substance
abuse or family history of mental illness. The
history below represents collateral information obtained from the patient’s family, given

the patient’s inability to answer questions. The
physical and mental status exams are depicted
in Table 1.

Events Leading to Current Admission

Forty days prior to the current admission, the
patient presented to the hospital postictally,
status post two consecutive seizures with left
facial droop. The initial CT scan showed a ringlike hyperdensity with vasogenic edema in the
periphery of the right frontal lobe with a mild
local mass effect. A follow-up MRI with con-

Table 1. Physical Examination, Laboratory Findings, and Mental Status Exam.
Mental Status Exam on Current
Physical Examination and Laboratory Findings
Admission

Physical Exam

Previous
Admission

Current
Admission

General
Assessment

Awake, alert x2
(person and time)

Cranial Nerves
intact, left facial
droop noted

Unremarkable,
no focal neurologic deficits

Appearance

Bizarre

Hgb: 11.5

Mood

Dysphoric, irritable

WBC: 18000

WBC: 6500

Affect

Blunt, labile

Na: 137

Na: 138

Behavior

Agitated

K: 3.7

K: 3.4

Attitude

Inhibited

Cr: 0.5

Cr: 0.3

Suicidal/Homicidal
ideation

Denies

BUN: 16

BUN: 7

Speech

Normal rate and
rhythm

AST/ALT: 21/34

AST/ALT: 29/40

Thought processes

Disorganized,
grossly impaired

ALP: 63

ALP: 75

Associations

Loose

Lactate: N/A

Lactate 3.3

Thought content

Bizarre, self-destructive ideation,
violent ideations

Total Bilirubin:
0.3

Total Bilirubin:
0.3

Hallucinations

Auditory and visual
hallucinations

Normal sinus
rhythm, QTc
410ms

No changes
from previous
ECG

Memory

Short term intact

Negative

Attention

Limited/poor

Insight/Judgement

Limited/poor

Significant Labs Hgb: 12.1

ECG

Urine Toxicology Negative
Serology

Positive Antibodies for
Taenia solium

Abbreviations: Hgb = Hemoglobin; WBC = White Blood Cell; Na = Sodium; K = Potassium;
Cr = Creatinine; BUN = Blood Urea Nitrogen; AST = Aspartate Aminotransferase; ALT = Alanine
Aminotransferase; ALP = Alkaline Phosphotase
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Figure 1. T2-weighted MRI with contrast taken on initial presentation.
trast showed a single cystic mass with thickened peripheral enhancement measuring 1.8 x
1.4 x 1.3 cm with surrounding vasogenic edema.
(Figures 1 & 2) Of note, no chronic signs of previous infection were visible (i.e., calcification).
Serologic testing confirmed the diagnosis of
neurocysticercosis. The patient was treated
with albendazole 600mg, dexamethasone 4mg
and levetiracetam 500mg twice daily for 1 week
in the hospital.
Upon discharge, the patient was instructed to
continue treatment with albendazole, levetiracetam and dexamethasone taper. The patient
maintained compliance with dexamethasone
and levetiracetam as prescribed, but due to difficulty in obtaining the albendazole, the patient
failed to adhere for 19 days. After 19 days from

discharge, the patient obtained albendazole
from Peru and initiated a dose of 200mg twice
daily (for a duration of 14 days, until current
admission).
During the time from discharge to the current
admission, the patient’s family noted progressive waxing and waning periods of neuropsychiatric decline with no return to baseline,
including episodes of depressed mood with
emotional lability and tearfulness, decreased
need for sleep, bizarre thought content, auditory hallucinations (derogatory content and
commands of self-harm), visual hallucinations
(seeing deceased family members) and paranoia. These symptoms started a few days after
discharge, during ongoing outpatient treatment with dexamethasone and levetiracetam,

Figure 2. T2-FLAIR MRI taken on initial presentation.
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Figure 3. T2-weighted MRI with contrast taken on current admission.
and still persisted after albendazole was introticosteroid-induced psychosis. Albendazole
duced 19 days post-discharge. In the few days
600mg (for a course duration of 14 days) and
leading up to the current admission, the family
levetiracetam 500mg twice daily was reinitiatreported increasing agitation with physical
ed. Despite steroid discontinuation, the patient
aggression (spitting on family members) and
continued to exhibit bizarre and grossly psyself-destructive behavior.
chotic behavior, with disorganized thought content, persistent agitation and physical aggression. Eight days later, the patient was deemed
Current Admission
medically cleared and transferred to the psychiThe patient was admitted to the medical unit
atric inpatient unit for further evaluation and
for AMS, with psychiatry, neurology and infecstabilization.
tious disease following the case. A repeat MRI
with contrast showed the same single cystic
mass with a reduction in size, now measuring
Assessment and Plan
1 x 0.8 x 0.7 cm, and a decrease in the surround- Upon further psychiatric evaluation, the patient
ing vasogenic edema. (Figures 3 & 4) As per
was diagnosed with Psychotic Disorder Due to
neurology, dexamethasone was discontinued
Another Medical Condition: Neurocysticercosis.
the day of admission due to concerns of corThe onset of the patient’s symptoms (Figure 5)

Figure 4. T2-FLAIR MRI taken on current admission.
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2012:
• Patient has first tonic clonic
seizure while living in Peru
• Treated for neurocystcercosis but has no follow-up

40 days prior to current admission:
• Patient has 2x seizure and is
admitted to the hospital
• MRI shows cystic lesion,
confirmed by serologic testing to be neurocystercosis

2012-2020:
• No seizures during this time
• Patient has intermittent
migraine headaches with
photophobia
• Patient has annual visits to
Peru

14 days prior to current admission:
• Patient begins taking
albendazole
• Family notices worsening
neuropsychiatric symptoms

33 days prior to current admission:
• Patient discharged home
but unable to continue
albendazole
• Onset of neuropsychiatric
symptoms

Figure 5. A timeline shows the events leading up to current admission.
correlate with the initiation of treatment of the cation regime and follow-up care in the outpaneurocysticercosis, with MRI imaging showing
tient setting.
persistent vasogenic edema in the right frontal
lobe. Given the lack of a previous personal or
Discussion
family psychiatric history, the new onset psyIn this report, the authors present a novel case
chotic symptoms could not be better explained of psychosis in the context of a recurrence of
by an underlying purely psychiatric disorder.
neurocysticercosis which, to the best of the
Corticosteroid, albendazole and levetiracetam
authors’ knowledge, is the first documented
induced psychosis were also deemed less likely
case within the US. During the patient’s initial
(rationale explored in discussion below).
incidence of neurocysticercosis in 2012, the paOlanzapine was initiated at 5mg orally (PO)
twice daily and titrated up to 10mg PO twice
daily over the course of 7 days. Olanzapine was
chosen for both its anti-psychotic and sedative effects, and the patient had no relative
contraindications such as metabolic syndrome.
Valproic acid 250mg PO two times daily was
initiated on day 7 to address extreme affect
lability. The patient displayed minimal improvement in thought process and lability. Aripiprazole 5mg PO daily was initiated based on the
theory of augmentation with D1 activation
within the mesocortical tract to assist with
negative symptomatology, such as flat affect,
and HT2a activation for anxiolysis. In addition,
valproic acid was titrated up to 250mg three
times daily on day 20. Repeat MRI showed
persistence of the lesion, which remained unchanged in size, with a decrease in size of the
surrounding edema on day 20. A long acting
injectable of risperidone, which was the second
generation long acting injectable carried on formulary by the hospital at that time, was given
on day 22 to bolster outpatient compliance. The
patient began to exhibit marked improvement
with psychiatric stability reached on day 23. The
patient was deemed stable for discharge with
recommendations of continued current medi-

tient presented solely with seizures. However,
during the second incidence, the patient also
presented with seizures, but later progressed
to symptoms suggestive of psychosis. Imaging
studies noted a single, acute stage cyst at the
same previous location after reported resolution, thus suggesting novel recurrence over
chronic complications.
In addition, the prolonged, multiple-admission
course of the second incidence of neurocysticercosis was complicated by previous medication noncompliance, with a delay in initiation
of albendazole upon discharge. Furthermore,
the discontinuation of steroids upon readmission is believed to have led to an increase in the
perilesional edema. Given the lack of a previous
personal or family psychiatric history, failure
of symptom resolution with discontinuation
of steroid adjuvant treatment, the presence
of AMS and visual hallucinations (suggesting
organic nature), along with the history, physical
examination findings and laboratory results as
reported in Table 1, the authors hypothesize
that the presentation of psychosis was secondary to the neurocysticercosis and its local
inflammatory response with surrounding vasogenic edema, with steroid-induced psychotic
disorder considered less likely.
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While the development of epilepsy is a
well-documented complication of neurocysticercosis, fewer studies have explored its associated neuropsychiatric manifestations.6 In a
study of 38 patients with neurocysticercosis in
Brazil, psychiatric illness and cognitive decline
were seen in 65.8% and 87.5% of cases, respectively.7 However, this study was considered an
outlier with controversy due to the fact that
these psychiatric manifestations were more
commonly seen in those patients with epilepsy,
ICH or hydrocephalus in an outpatient neurology clinic.8,9 Depression was the most commonly reported psychiatric complication, and
while schizophrenia and mania-like episodes
have been reported as initial symptoms of
neurocysticercosis, such features occur in only
about 4.5% of cases in the literature.7,10,11 Other
studies on psychiatric manifestations of neurocysticercosis have documented no patients
with psychotic features.8,12 To date, there have
been only two documented cases of psychosis
in the initial presentation of patients affected
by neurocysticercosis, both of which occurred
in India.4,5
Almost all medications, substances or medical conditions affecting the CNS can present
with psychiatric symptoms, including acute
psychosis. Psychosis is typically defined as “any
impairment in reality testing, encompasses
delusions, hallucinations, thought disorder, and
disorganized behavior”.13 Despite the existence
of reliable or definitive features distinguishing
primary versus secondary psychosis, comorbid
medical conditions or substance use should
be suspected and investigated in patients
presenting with atypical psychotic features.
Suggested atypical features include later age
of onset, no family history of a psychotic disorder, psychosis with cognitive impairment, AMS
and/or visual or multimodal hallucinations.14,15
According to the DSM-V criteria, a psychotic disorder due to another medical condition
must have history, physical examination and/or
laboratory findings to indicate that the disturbance is a pathophysiological consequence of
the medical condition. In a substance/medication induced psychotic disorder, symptoms
must have developed soon after intoxication
or withdrawal from a substance/medication
capable of causing the symptoms, and the psychotic symptoms are not better described by
another psychotic disorder that is not related
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to the medical condition or substance/medication use.16
The patient initially presented following a seizure, and the diagnosis of neurocysticercosis
was confirmed by MRI and serologic testing.
There were no other significant physical examination or laboratory findings. (Table 1) However, the patient’s psychotic symptoms did not
begin until 1 week after beginning treatment
with albendazole and dexamethasone while
inpatient. The severity of psychiatric symptoms in neurocysticercosis may be correlated
with the course of antiparasitic treatment due
to the increase in local inflammation, however, the precise mechanism is not well understood.7,10 In inflammatory states, the integrity
of the blood-brain barrier (BBB) is reduced.17
This allows extensive leukocyte migration into
the CNS and facilitates the development of
vasogenic edema.17,18 Research suggests that
inflammation, edema and alterations in cerebrospinal fluid pressure may play a role in the
development of psychotic and depressive disorders.19 As shown in Figures 1–4, the vasogenic
edema present in the right frontal lobe continued, although with a noted decrease, in the
33 days following discharge from the hospital,
following the onset of the patient’s psychotic
symptoms. In addition, incomplete adherence
to the albendazole may have led to incomplete
degeneration of the cyst. Studies suggest that
calcified or degenerating cysts are more likely
to be symptomatic, but the generalizability of
the data is limited due to the long-standing
nature of the neurocysticercosis within the
sample populations.8,10,12,20 Given the acute onset of psychotic features following initiation of
treatment, incomplete cyst degeneration and
persistence of vasogenic edema seen on the
MRI, and low suspicion of a primary psychiatric
disorder with no family or personal psychiatric
history, the diagnosis of Psychotic Disorder
Due to Another Medical Condition: Neurocysticercosis was determined.
Corticosteroid use is currently recommended
alongside cysticidal medications, unless otherwise contraindicated, due to the reduction
in cerebral edema alongside other anti-inflammatory effects2,21 It is important to recall that
corticosteroid treatment for any medical condition has been well documented as a causative
agent of many neuropsychiatric effects. These
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effects have been described as occurring in
30-60% of all patients receiving corticosteroid
treatment for any cause, with varying severity.22–24 Mood disturbances such as depression
and mania, with respective prevalence of up to
35% and 31%, are the most common psychiatric
symptoms associated with steroid use. Other,
significantly less common neuropsychiatric
manifestations include psychosis, delirium and
cognitive deficits.22,25 The majority of patients
develop symptoms within 2 weeks of initiating
corticosteroids, although symptoms can develop at any time.24 Dose-dependent severity of
symptoms is reported, which typically resolve
within a week of discontinuation of steroids,
either abruptly or with dose tapering.23 Additionally, long term use of corticosteroids may
lead to persistent effects with longer time to
resolution.22,24
In this case, the patient’s clinical presentation
was inconsistent with corticosteroid-induced
psychosis. The patient’s symptoms primarily consisted of delusions, auditory and visual
hallucinations, and bizarre thought processes,
with episodes of depressed mood and emotional lability. Furthermore, steroids were
discontinued upon readmission, but psychotic
symptoms persisted.
While the literature reports a case of albendazole inducing psychosis,27 in the case discussed
here, psychotic symptoms arose in the 19 days
before albendazole was even initiated. Levetiracetam can also induce psychosis, as noted
in the original drug trials as a rare but potential side effect.28 However, during the current
admission when patient was continuously
maintained on levetiracetam for seizure prophylaxis, drastic improvement in psychotic and
affective symptoms were still noted, making
levetiracetam-induced psychosis less likely. It
is theoretically possible that the initiation of
anti-psychotic medication during the current
admission started masking the side effects of
the levetiracetam. A reemergence of psychotic
symptoms in the outpatient setting when anti-psychotics were discontinued and levetiracetam maintained would push this higher on the
differential. However, to our knowledge, there
was no reemergence of psychosis or other psychiatric symptoms after discharge.
The recurrent nature of neurocysticercosis depicted in this case remains an enigma in current

literature, with only one report of recurrent
incidence in an endemic area.26 Contributing
factors in this particular case presentation may
include a higher infection propensity with repeated visits to Peru, an area of higher disease
prevalence. Additionally, immunosuppression,
along with reduced efficacy of the BBB for
any reason, could also play contributing roles.
Further research could elucidate the recurrent
and/or persistent nature and contributing
progressive factors of this CNS infection, and
possibly aid in the development of optimal
management and preventative measures with
future infections.

Conclusion

The authors describe the first documented
case of Psychotic Disorder Due to Another
Medical Condition: Neurocysticercosis in the
context of the second recurrence of neurocysticercosis in a patient presenting with neuropsychiatric instability in the US. The authors
postulate that the atypical presentation of
acute psychosis during the aberrant recurrence
of neurocysticercosis is predominantly attributable to the parasitic infection itself, along with
its resultant cyst formation and inflammatory
response. Future evaluation and investigation is
necessary to expand upon our knowledge and
understanding of the neuropsychiatric effects
and optimal management of neurocysticercosis, as well as its possible recurrent nature.
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